

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Running title: Dimethyl fumarate for COVID-19

RECOVERY Collaborative Group*

*The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: recoverytrial@ndph.ox.ac.uk

Dimethyl fumarate for COVID-19

22 SUMMARY

23 **Background:** Dimethyl fumarate (DMF) is an anti-inflammatory drug that has been
24 proposed as a treatment for patients hospitalised with COVID-19.

25 **Methods:** This randomised, controlled, open-label platform trial (Randomised Evaluation
26 of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in
27 patients hospitalised for COVID-19. In this initial assessment of DMF, performed at 27
28 UK hospitals, eligible and consenting adults were randomly allocated (1:1) to either usual
29 standard of care alone or usual standard of care plus DMF 120mg twice daily for 2 days
30 followed by 240mg twice daily for 8 days, or until discharge if sooner. The primary
31 outcome was clinical status on day 5 measured on a seven-point ordinal scale, assessed
32 using a proportional odds model. Secondary outcomes were time to sustained
33 improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day
34 5 C-reactive protein, and improvement in day 10 clinical status. The trial is registered with
35 ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

36

37 **Findings:** Between 2 March 2021 and 18 November 2021, 713 patients were enrolled in
38 the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus
39 DMF, and 357 to usual care alone. 95% of patients were receiving corticosteroids as part
40 of routine care. There was no evidence of a beneficial effect of DMF on clinical status at
41 day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.85-1.46; $p=0.42$).
42 There was no significant effect of DMF on any secondary outcome. As expected, DMF
43 caused flushing and gastrointestinal symptoms, each in around 6% of patients, but no
44 new adverse effects were identified.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

45 **Interpretation:** In adults hospitalised with COVID-19, DMF was not associated with an
46 improvement in clinical outcomes.

47 **Funding:** UK Research and Innovation (Medical Research Council) and National Institute
48 of Health Research (Grant ref: MC_PC_19056).

49 **Keywords:** COVID-19, dimethyl fumarate, DMF, clinical trial.

50

Dimethyl fumarate for COVID-19

51 INTRODUCTION

52 Severe COVID-19 is characterised by marked inflammation of the lungs, which causes
53 respiratory failure and is usually associated with elevated circulating inflammatory
54 markers such as C-reactive protein (CRP) and interleukin-6 (IL-6).¹⁻⁴ This has led to the
55 evaluation of several different kinds of immunomodulation in the treatment of severe
56 COVID-19. Corticosteroids, IL-6 inhibitors, and Janus kinase inhibitors have all been
57 found to reduce mortality in hospitalised patients, although the risk of death remains high
58 even when these treatments are used.⁵⁻⁸ The effectiveness of these drugs proves that
59 inflammation is a modifiable cause of death in patients with COVID-19, and suggests that
60 other ways of modifying the immune response might also be beneficial.

61 Inflammasomes are part of the innate immune response, and have been proposed as
62 important mediators of COVID-19 lung disease.^{9,10} These cytosolic pattern recognition
63 receptor systems stimulate the release of proinflammatory cytokines and activate
64 inflammatory cell death (pyroptosis).¹¹ In COVID-19, the degree of inflammasome
65 activation, particularly of the NLRP3 inflammasome, correlates with disease severity.¹²
66 However, although this pathway has been identified as a promising therapeutic target,
67 treatment with colchicine, which inhibits NLRP3 inflammasome activation, does not
68 improve outcomes in hospitalised patients.¹³ Dimethyl fumarate (DMF) is thought to inhibit
69 NLRP3 inflammasome activation via a different mechanism to colchicine, by inactivating
70 gasdermin D, and has been found to have anti-viral and anti-inflammatory effects against
71 SARS-CoV-2 *in vitro*^{14,15}. It is licensed to treat relapsing remitting multiple sclerosis and
72 plaque psoriasis, and is generally well-tolerated, although often associated with flushing

Dimethyl fumarate for COVID-19

73 and gastrointestinal symptoms on initiation^{16,17}. As part of the UK COVID-19 Therapeutics
74 Advisory Panel (CTAP) review of possible therapeutics for evaluation in clinical trials,
75 CTAP recommended to the RECOVERY chief investigators that DMF be investigated in
76 an early phase assessment among hospitalised patients, with subsequent assessment in
77 a larger trial of its effect on mortality if there was evidence of efficacy on surrogate
78 outcomes. Here we report the results of an early phase randomised assessment of DMF
79 in patients hospitalised with COVID-19, performed as part of the RECOVERY platform
80 trial.

81

82 **METHODS**

83 **Study design and participants**

84 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-
85 initiated, streamlined, individually randomised, controlled, open-label, platform trial to
86 evaluate the effects of potential treatments in patients hospitalised with COVID-19.
87 Details of the trial design and results for other possible treatments (dexamethasone,
88 hydroxychloroquine, lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma,
89 colchicine, aspirin, casirivimab plus imdevimab, and baricitinib) have been published
90 previously.^{6–8,13,18–23} The trial is underway at 177 hospital organisations in the United
91 Kingdom supported by the National Institute for Health and Care Research Clinical
92 Research Network, and also at 15 non-UK hospitals (appendix pp 3-29). Of these, 27 UK
93 hospitals participated in the DMF comparison. The trial is coordinated by the Nuffield
94 Department of Population Health at the University of Oxford (Oxford, UK), the trial

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

95 sponsor. The trial is conducted in accordance with the principles of the International
96 Conference on Harmonisation–Good Clinical Practice guidelines and approved by the UK
97 Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East
98 Research Ethics Committee (ref: 20/EE/0101). The protocol and statistical analysis plan
99 are included in the appendix (pp 61-172) with additional information available on the study
100 website www.recoverytrial.net.

101 Patients admitted to hospital were eligible for the study if they had clinically suspected or
102 laboratory confirmed COVID-19 and no medical history that might, in the opinion of the
103 attending clinician, put the patient at significant risk if they were to participate in the trial.
104 Those aged <18 years and pregnant women were not eligible for randomisation to DMF.
105 Written informed consent was obtained from all patients, or a legal representative if
106 patients were too unwell or otherwise unable to provide informed consent.

107 **Randomisation and masking**

108 Baseline data were collected using a web-based case report form that included patient
109 demographics, level of respiratory support, major comorbidities, suitability to receive the
110 study treatment, and treatment availability at the study site (appendix pp 38-40). Eligible
111 and consenting patients were assigned in a 1:1 ratio to either usual standard of care or
112 usual standard of care plus DMF using web-based simple (unstratified) randomisation
113 with allocation concealed until after randomisation (appendix pp 36-38). For some
114 patients, DMF was unavailable at the hospital at the time of enrolment or was considered
115 by the managing physician to be either definitely indicated or definitely contraindicated.
116 These patients were not eligible for randomisation between DMF and usual care. Patients

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

117 allocated DMF were to receive 120mg by mouth every 12 hours for the first 4 doses,
118 followed by 240mg every 12 hours, for total treatment duration of 10 days or until hospital
119 discharge, whichever was sooner. The stepped increase in dose was chosen to minimise
120 flushing and gastrointestinal side effects, and the protocol also allowed dose reduction to
121 a minimum of 120mg once daily if needed to control side effects.

122 As a platform trial, and in a factorial design, patients could be simultaneously randomised
123 to other treatment groups: i) casirivimab plus imdevimab versus usual care, ii) aspirin
124 versus usual care, iii) baricitinib versus usual care, and iv) empagliflozin versus usual
125 care. Further details of when these factorial randomisations were open are provided in
126 the supplementary appendix (pp 36-38). Participants and local study staff were not
127 masked to the allocated treatment. The trial steering committee, investigators, and all
128 other individuals involved in the trial were masked to outcome data during the trial.

129 **Procedures**

130 Participants had daily assessment of clinical status from day 1 to day 10, using a seven-
131 category ordinal scale as follows: 1) discharged alive; 2) in hospital, not requiring oxygen
132 or medical care; 3) in hospital, not requiring oxygen but requiring medical care; 4) in
133 hospital, requiring oxygen via simple face mask or nasal cannula; 5) in hospital, requiring
134 high-flow nasal oxygen or non-invasive ventilation; 6) in hospital, requiring invasive
135 mechanical ventilation or extracorporeal membrane oxygenation; and 7) dead.²⁴ At
136 baseline and on days 3, 5 and 10, the S/F₉₄ ratio was recorded. The S/F₉₄ ratio is defined
137 as the ratio of peripheral oxygen saturations (SpO₂) to the fraction of inspired oxygen
138 (FiO₂), with any supplemental oxygen reduced until SpO₂ is <94% (patients were

Dimethyl fumarate for COVID-19

139 transferred to an oxygen delivery device providing a defined FiO_2 if necessary). Details of
140 S/F_{94} measurement and its rationale are outlined in the appendix (pp 30, 139-151).
141 Derivation and evaluation of the S/F_{94} endpoint are reported in a companion paper.²⁵
142 Blood C-reactive protein, creatinine and alanine or aspartate transaminase were
143 measured on days 3, 5 and 10, along with treatment adherence and details of adverse
144 events. The above details were collected into a web-based DMF follow up form developed
145 for this early phase assessment, completed daily until day 10 (appendix pp 41-45).
146 Another online follow-up form was completed when participants were discharged, had
147 died or at 28 days after randomisation, whichever occurred earliest (appendix pp 46-53).
148 This recorded information on receipt of other COVID-19 treatments, duration of
149 admission, receipt of respiratory or renal support, and vital status (including cause of
150 death). In addition, routine healthcare and registry data were obtained including
151 information on vital status (with date and cause of death), discharge from hospital, receipt
152 of respiratory support, or renal replacement therapy.

153 **Outcomes**

154 The primary outcome was clinical status at day 5, as assessed on the ordinal scale.
155 Secondary outcomes were: time to sustained improvement by at least one category on
156 the ordinal scale from baseline (persisting for >1 day), time to discharge from hospital,
157 S/F_{94} ratio at day 5, blood C-reactive protein at day 5, and improvement in clinical status
158 by at least one category at day 10. The initial protocol specified day 5 S/F_{94} as the primary
159 outcome and day 5 clinical status as a secondary outcome, but these were switched in
160 October 2021 when it was realised that discharges before day 5 would lead to significant

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

161 amounts of missing data for the S/F₉₄ outcome. This decision was made by the trial
162 investigators whilst blinded to the results of the DMF comparison.

163 Subsidiary clinical outcomes were: use of ventilation and, separately, use of renal dialysis
164 or haemofiltration, among patients not on such treatment at randomisation, and
165 thrombotic events. Pre-specified safety outcomes were: flushing, gastrointestinal
166 symptoms, transaminitis (peak ALT/AST >3x upper limit of normal), acute kidney injury
167 (peak creatinine >1.5x value at randomisation), cause-specific mortality, bleeding events,
168 major cardiac arrhythmias, and non-coronavirus infections. Information on suspected
169 serious adverse reactions was collected in an expedited fashion to comply with regulatory
170 requirements.

171 **Statistical Analysis**

172 The primary analysis for all outcomes was by intention-to-treat, comparing patients
173 randomised to DMF with patients randomised to usual care. For the primary outcome of
174 clinical status at day 5, the common odds ratio of a worse outcome with DMF versus usual
175 care was estimated using ordinal logistic regression with adjustment for baseline score.
176 For 20 participants still alive in hospital on day 5 without a recorded score, the median
177 possible score was imputed. The proportional odds assumption was assessed and there
178 was no evidence that this was violated (p-value from test of proportional odds assumption
179 0.95).

180 For time to sustained improvement, the log-rank observed minus expected statistic and
181 its variance were used to test the null hypothesis of equal survival curves (i.e., the log-
182 rank test) and to calculate the one-step estimate of the average rate ratio. Analyses

Dimethyl fumarate for COVID-19

183 were restricted to the first 10 days as ordinal scores were not collected after this. A
184 similar analysis was used for time to discharge up to day 28, with patients who died in
185 hospital right-censored on day 29. Median time to discharge was derived from Kaplan-
186 Meier estimates.

187 Comparisons of S/F₉₄ ratio and log-transformed CRP at day 5 were performed using
188 ANCOVA adjusted for each participant's baseline value. For patients who were
189 discharged from hospital, for whom it was not possible to measure S/F₉₄ ratio at day 5, a
190 value of 4.76 was imputed (i.e. the maximum value, assuming saturations of 100% when
191 breathing 21% oxygen). Multiple imputation methods were used to account for any other
192 missing data.²⁶ Risk ratios were used to compare treatment arms for improvement of
193 clinical status at day 10, and for all subsidiary and safety outcomes.

194 Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values
195 are 2-sided and are shown without adjustment for multiple testing. The full database is
196 held by the study team, which collected the data from study sites and performed the
197 analyses at the Nuffield Department of Population Health, University of Oxford (Oxford,
198 UK).

199 It was estimated that enrollment of at least 700 patients would provide 80% power (at
200 $2p=0.05$) to detect a common odds ratio of 0.67, even if 10% of participants discontinued
201 study treatment before day 5. Recruitment was halted on 19th November 2021 after target
202 recruitment had been reached. The Trial Steering Committee and all other individuals
203 involved in the trial were masked to outcome data until 28 days after the close of
204 recruitment.

Dimethyl fumarate for COVID-19

205 Analyses were performed using SAS version 9.4 and R version 3.4. The trial is registered
206 with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

207 **Role of the funding source**

208 The funder of the study had no role in study design, data collection, data analysis, data
209 interpretation, or writing of the report. DMF was provided from standard National Health
210 Service stocks. The corresponding authors had full access to all the data in the study and
211 had final responsibility for the decision to submit for publication.

212

213 **RESULTS**

214 Between 2 March 2021 and 18 November 2021, 713 (44%) of 1630 patients enrolled into
215 the RECOVERY trial at sites participating in the DMF comparison were eligible to be
216 randomly allocated to DMF (i.e. consent was obtained, DMF was available in the hospital
217 at the time and the attending clinician was of the opinion that the patient had no known
218 indication for or contraindication to DMF, figure 1). 356 patients were randomly allocated
219 to DMF plus usual standard of care and 357 were randomly allocated to usual standard
220 of care alone. The mean age of study participants in this comparison was 57.1 years (SD
221 15.7) and the median time since symptom onset was 9 days (IQR 7 to 11 days) (table 1).
222 At randomisation, 40 (6%) patients did not require oxygen, 535 (75%) required simple
223 oxygen without ventilation, and 135 (19%) required non-invasive ventilation. 674 (95%)
224 were receiving corticosteroids.

Dimethyl fumarate for COVID-19

225 Among patients with known DMF adherence, 306/331 (92%) allocated to DMF received
226 at least one dose, and 248/331 (75%) received at least half of the specified treatment
227 course. Use of other treatments for COVID-19 was similar among patients allocated DMF
228 and those allocated usual care, including use of baricitinib (44% of participants), and
229 tocilizumab or sarilumab (34% of participants) (webtable 1).

230 Primary outcome data are known for 693 (97%) of randomly assigned patients. There
231 was no significant difference between the groups in clinical status at day 5 (common odds
232 ratio of unfavourable outcome 1.12; 95% confidence interval [CI] 0.85–1.46; $p=0.42$; table
233 2, figures 2 and 3).

234 We found no evidence of an effect of DMF on any secondary or subsidiary outcome (table
235 2). There was no significant difference in the time to sustained clinical improvement (rate
236 ratio 0.96; 95% CI 0.80–1.16, $p=0.70$) or time to discharge from hospital alive (rate ratio
237 0.95, 95% CI 0.80–1.13, $p=0.59$). At day 5 after randomisation there was no significant
238 difference in S/F₉₄ (difference in mean S/F₉₄ -0.06; 95% CI -0.22 to 0.10; $p=0.45$) or in
239 CRP (difference in geometric mean 2%; 95% CI -18% to 29%; $p=0.84$). The proportion of
240 patients with improvement of clinical status by day 10 was similar in both groups (risk
241 ratio 0.95; 95% CI 0.87–1.05; $p=0.31$).

242 Compared to usual care, more participants allocated to DMF suffered flushing (9% vs 3%,
243 risk ratio 2.81; 95% CI 1.44–5.50; $p=0.003$) and gastrointestinal symptoms (11% vs 5%,
244 risk ratio 1.99; 95% CI 1.17–3.39; $p=0.01$, table 2). DMF treatment was discontinued
245 because of adverse events in 42 (13%) patients, mainly because of flushing, rash,
246 diarrhoea, or abnormal liver function tests, and 12 (4%) patients required DMF dose

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

247 reduction (webtable 2). A further 32 (10%) patients discontinued DMF for reasons other
248 than adverse events, mainly because they were no longer able to take tablets (webtable
249 2). There was one report of a serious adverse reaction believed related to DMF, in a
250 patient whose ALT rose to 5 times the upper limit of normal, although the total number of
251 patients with transaminitis reported was similar in both groups (19% vs 18%, risk ratio
252 1.05; 95% CI 0.75-1.46; p=0.78, table 2). There was no evidence of an effect of DMF on
253 other safety outcomes, including all-cause mortality, cause-specific mortality, cardiac
254 arrhythmia, non-coronavirus infections, acute kidney injury, thrombotic events or bleeding
255 events (table 2, webtables 3-5).

256

257 **DISCUSSION**

258 In this initial evaluation in the RECOVERY trial, involving over 700 patients hospitalised
259 with COVID-19, treatment with DMF was not associated with improvement in any clinical
260 outcome compared with usual care alone. This is the first randomised trial of DMF for the
261 treatment of COVID-19, and although pre-clinical data suggest that it interferes with
262 inflammatory pathways important to the pathogenesis of COVID-19 pneumonia, this did
263 not translate into any evident benefit of treatment.

264 Inflammasome-mediated inflammation is activated in patients with severe COVID-19,
265 making it a promising therapeutic target. DMF effectively inhibits inflammasome activation
266 in vitro and is effective as an anti-inflammatory treatment for psoriasis and relapsing-
267 remitting multiple sclerosis (where it halves the rate of relapse).¹⁵⁻¹⁷ However, colchicine
268 and DMF have both now been evaluated in hospitalised COVID-19 patients because they

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

269 interfere with inflammasome activation, and neither has produced any discernible
270 improvement in outcome. This may be because these agents do not block this pathway
271 effectively enough, or because activation of this pathway is not causally related to disease
272 trajectory, at least among hospitalised patients receiving current standard treatment.
273 Corticosteroids were received by 95% of the trial population, and a significant proportion
274 also received an IL-6 inhibitor or JAK inhibitor. It is possible that DMF could have had a
275 beneficial effect in the absence of other immunomodulators, but it appears to add little or
276 nothing to current usual care.

277 Treatment was discontinued because of adverse events in 13% of patients, mostly
278 because of flushing, rash, and gastrointestinal side-effects. These are recognised side-
279 effects of DMF, although rarely caused discontinuation in outpatient placebo-controlled
280 trials in patients with multiple sclerosis.^{16,17} Other than these adverse effects, no safety
281 concerns of DMF treatment were identified. DMF was discontinued because of abnormal
282 liver function tests in 6 patients, but ALT elevations are commonly seen in hospitalised
283 patients with COVID and occurred in 18% of participants in the usual care arm.²⁷ The
284 proportion of patients with transaminitis was similar in the DMF and usual care groups,
285 suggesting DMF was not a significant cause of transaminitis, and highlighting the need
286 for systematic data collection when evaluating adverse events in an open label study.

287 Strengths of this trial include that it was randomised, had broad eligibility criteria, and
288 follow up was 97% complete. However, there are some limitations: as an early phase
289 study, it was not large enough to rule out a benefit in mortality, nor to assess whether
290 treatment effects might have varied among specific groups of patients. The trial was open
291 label, so participants and local hospital staff were aware of the assigned treatment. This

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

292 could potentially affect the assessment of some outcomes, particularly if allocation to
293 DMF led to patients staying in hospital to receive treatment rather than being discharged.
294 However, our protocol specified that treatment was to stop when patients were ready for
295 discharge, and the distribution of clinical status at day 5 provides no evidence to suggest
296 that otherwise healthy patients stayed in hospital to receive DMF (Figures 2 and 3).
297 Finally, we only studied patients who had been hospitalised with COVID-19, so do not
298 provide any evidence on the safety and efficacy of DMF in other groups, such as
299 outpatients.

300 In summary, the results of this randomised trial do not support the use or further study of
301 DMF in adults hospitalised with COVID-19.

302

Dimethyl fumarate for COVID-19

303 **Evidence before this study:**

304 We searched PubMed, medRxiv, bioRxiv, and the WHO International Clinical Trials
305 Registry Platform from September 1, 2019 to July 31, 2022 for clinical trials evaluating
306 the effect of dimethyl fumarate treatment in patients with COVID-19, using the search
307 terms (SARS-CoV-2 OR COVID OR COVID-19 OR 2019-nCoV OR Coronavirus) AND
308 (dimethyl fumarate OR Tecfidera OR Skilarence OR BG-12). We did not identify any
309 reported trials.

310

311 **Added value of this study:**

312 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is the first
313 randomised trial to report results of the effect of dimethyl fumarate in patients with COVID-
314 19. We found no significant effect of DMF compared with usual care alone on clinical
315 status at day 5, or any other clinical outcomes.

316

317 **Implications of all the available evidence:**

318 There is no evidence that treatment with dimethyl fumarate is of clinical benefit for adults
319 hospitalised with COVID-19 compared with current usual care.

320

Dimethyl fumarate for COVID-19

321 **Contributors**

322 This manuscript was initially drafted by LP, PWH and MJL. All authors contributed to data
323 interpretation and critical review and revision of the manuscript. PWH and MJL vouch for
324 the data and analyses, and for the fidelity of this report to the study protocol and data
325 analysis plan. PWH, MM, JKB, MHB, JD, SNF, TJ, KJ, EJ, MK, WSL, AMo, AMu, KR, GT,
326 RH, and MJL designed the trial and study protocol. LP, MC, G P-A, MM, RS, BP, AU,
327 CAG, DJD, FM, JM, PC, JS, BY, and the Data Linkage team at the RECOVERY
328 Coordinating Centre, and the Health Records and Local Clinical Centre staff listed in the
329 appendix collected the data. NS and JRE had access to the study data and did the
330 statistical analysis. PWH and MJL had final responsibility for the decision to submit for
331 publication.

332 **Writing Committee (on behalf of the RECOVERY Collaborative Group):**

333 Peter W Horby,* Leon Peto,* Natalie Staplin,* Mark Campbell, Guilherme Pessoa-
334 Amorim, Marion Mafham, Jonathan R Emberson, Richard Stewart, Benjamin Prudon,
335 Alison Uriel, Christopher A Green, Devesh J Dhasmana, Flora Malein, Jaydip Majumdar,
336 Paul Collini, Jack Shurmer, Bryan Yates, J Kenneth Baillie, Maya H Buch, Jeremy Day,
337 Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen
338 Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Richard
339 Haynes,† Martin J Landray.†

340 **Data Monitoring Committee**

341 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,
342 Mohammed Munavvar, Adilia Warris, Janet Wittes.

Dimethyl fumarate for COVID-19

343 **Declaration of interests**

344 The authors have no conflict of interest or financial relationships relevant to the submitted
345 work to disclose. No form of payment was given to anyone to produce the manuscript. All
346 authors have completed and submitted the ICMJE Form for Disclosure of Potential
347 Conflicts of Interest. The Nuffield Department of Population Health at the University of
348 Oxford has a staff policy of not accepting honoraria or consultancy fees directly or
349 indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-independence-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)
350 [of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

351 **Data sharing**

352 The protocol, consent form, statistical analysis plan, definition & derivation of clinical
353 characteristics & outcomes, training materials, regulatory documents, and other relevant
354 study materials are available online at www.recoverytrial.net. As described in the protocol,
355 the trial Steering Committee will facilitate the use of the study data and approval will not
356 be unreasonably withheld. Deidentified participant data will be made available to bona
357 fide researchers registered with an appropriate institution within 3 months of publication.
358 However, the Steering Committee will need to be satisfied that any proposed publication
359 is of high quality, honours the commitments made to the study participants in the consent
360 documentation and ethical approvals, and is compliant with relevant legal and regulatory
361 requirements (e.g. relating to data protection and privacy). The Steering Committee will
362 have the right to review and comment on any draft manuscripts prior to publication. Data
363 will be made available in line with the policy and procedures described at:

Dimethyl fumarate for COVID-19

364 <https://www.ndph.ox.ac.uk/data-access>. Those wishing to request access should
365 complete the form at
366 https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx
367 and e-mail to: data.access@ndph.ox.ac.uk

368

369 **Acknowledgements**

370 Above all, we would like to thank the patients who participated in this trial. We would also
371 like to thank the many doctors, nurses, pharmacists, other allied health professionals, and
372 research administrators at NHS hospital organisations across the whole of the UK,
373 supported by staff at the National Institute of Health Research (NIHR) Clinical Research
374 Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the
375 Intensive Care National Audit & Research Centre, Public Health Scotland, National
376 Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at
377 University of Swansea, and the NHS in England, Scotland, Wales and Northern Ireland.

378 The RECOVERY trial is supported by grants to the University of Oxford from UK Research
379 and Innovation (UKRI) and NIHR (MC_PC_19056), the Wellcome Trust (Grant Ref:
380 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding
381 provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill
382 and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office,
383 Health Data Research UK, the Medical Research Council Population Health Research
384 Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR
385 Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical

It is made available under a [CC-BY 4.0 International license](#) .

Dimethyl fumarate for COVID-19

386 Research Council (MC_UU_0002/14). WSL is supported by core funding provided by
387 NIHR Nottingham Biomedical Research Centre. Tocilizumab was provided free of charge
388 for this trial by Roche Products Limited. Regeneron Pharmaceuticals supported the trial
389 through provision of casirivimab and imdevimab. The views expressed in this publication
390 are those of the authors and not necessarily those of the NHS, the NIHR, or the UK
391 Department of Health and Social Care. For the purpose of Open Access, the author has
392 applied a CC BY public copyright licence to any Author Accepted Manuscript version
393 arising from this submission.

394

Dimethyl fumarate for COVID-19

395 References

- 396 1 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to
397 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive*
398 *Care Med* 2020; **46**: 846–8.
- 399 2 McElvaney OJ, McEvoy NL, McElvaney OF, *et al.* Characterization of the
400 Inflammatory Response to Severe COVID-19 Illness. *Am J Respir Crit Care Med* 2020;
401 **202**: 812–21.
- 402 3 Wang J-H, Chen R-D, Yang H-K, *et al.* Inflammation-associated factors for
403 predicting in-hospital mortality in patients with COVID-19. *J Med Virol* 2021; **93**: 2908–
404 17.
- 405 4 Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, *et al.* Inflammatory
406 profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe
407 COVID-19. *Sci Immunol* 2021; **6**: eabg9873.
- 408 5 The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working
409 Group. Association Between Administration of Systemic Corticosteroids and Mortality
410 Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* 2020; **324**: 1330–
411 41.
- 412 6 RECOVERY Collaborative Group, Horby P, Lim WS, *et al.* Dexamethasone in
413 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**: 693–704.
- 414 7 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
415 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
416 *Lancet Lond Engl* 2021; **397**: 1637–45.
- 417 8 RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with
418 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and
419 updated meta-analysis. *Lancet Lond Engl* 2022; **400**: 359–68.
- 420 9 Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe
421 COVID-19. *Nat Rev Immunol* 2021; **21**: 694–703.
- 422 10 Kaivola J, Nyman TA, Matikainen S. Inflammasomes and SARS-CoV-2 Infection.
423 *Viruses* 2021; **13**: 2513.
- 424 11 Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and
425 signalling. *Nat Rev Immunol* 2016; **16**: 407–20.
- 426 12 Rodrigues TS, de Sá KSG, Ishimoto AY, *et al.* Inflammasomes are activated in
427 response to SARS-CoV-2 infection and are associated with COVID-19 severity in
428 patients. *J Exp Med* 2021; **218**: e20201707.

Dimethyl fumarate for COVID-19

- 429 13 RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with
430 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*
431 *Respir Med* 2021; **9**: 1419–26.
- 432 14 Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, *et al.* Succination inactivates
433 gasdermin D and blocks pyroptosis. *Science* 2020; **369**: 1633–7.
- 434 15 Olagnier D, Farahani E, Thyrssted J, *et al.* SARS-CoV2-mediated suppression of
435 NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-
436 itaconate and dimethyl fumarate. *Nat Commun* 2020; **11**: 4938.
- 437 16 Gold R, Kappos L, Arnold DL, *et al.* Placebo-controlled phase 3 study of oral BG-
438 12 for relapsing multiple sclerosis. *N Engl J Med* 2012; **367**: 1098–107.
- 439 17 Fox RJ, Miller DH, Phillips JT, *et al.* Placebo-controlled phase 3 study of oral BG-
440 12 or glatiramer in multiple sclerosis. *N Engl J Med* 2012; **367**: 1087–97.
- 441 18 RECOVERY Collaborative Group, Horby P, Mafham M, *et al.* Effect of
442 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020; **383**:
443 2030–40.
- 444 19 RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to
445 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform
446 trial. *Lancet Lond Engl* 2020; **396**: 1345–52.
- 447 20 RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
448 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
449 *Lancet Lond Engl* 2021; **397**: 605–12.
- 450 21 RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
451 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform
452 trial. *Lancet Lond Engl* 2021; **397**: 2049–59.
- 453 22 RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with
454 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*
455 *Lond Engl* 2021; : S0140-6736(21)01825-0.
- 456 23 RECOVERY Collaborative Group. Casirivimab and imdevimab in patients
457 admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
458 label, platform trial. *Lancet Lond Engl* 2022; **399**: 665–76.
- 459 24 Goldman JD, Lye DCB, Hui DS, *et al.* Remdesivir for 5 or 10 Days in Patients
460 with Severe Covid-19. *N Engl J Med* 2020; **383**: 1827–37.
- 461 25 Swets MC, Kerr S, Scott-Brown J, *et al.* Evaluation of S/F94 as a proxy for
462 COVID-19 severity. *Medrxiv* URL TBD (accessed Sept 23, 2022).
- 463 26 Rubin, D. Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons,
464 Inc., 1987.

It is made available under a [CC-BY 4.0 International license](#) .

Dimethyl fumarate for COVID-19

465 27 Bertolini A, van de Peppel IP, Bodewes FAJA, *et al.* Abnormal Liver Function
466 Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. *Hepato/*
467 *Baltim Md* 2020; **72**: 1864–72.

468

Dimethyl fumarate for COVID-19

469 **Figures**

470 **Figure 1: Trial profile**

471 ITT=intention to treat. * Number recruited overall at sites participating in the DMF
472 comparison during the period that adult participants could be recruited. DMF
473 unavailable and DMF unsuitable are not mutually exclusive.

474 **Figure 2: Distribution of clinical ordinal scale at 5 days by randomised allocation**

475 **Figure 3: Effects of allocation to dimethyl fumarate on relative odds of a bad** 476 **outcome on the clinical ordinal scale at day 5, for each alternative definition of** 477 **bad outcome**

478 Odds ratio estimates for each ordinal scale comparison are represented by squares (with
479 areas of the squares proportional to the amount of statistical information) and the lines
480 through them correspond to the 95% CIs.

481

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Dimethyl fumarate for COVID-19

482 **Table 1: Baseline characteristics of patients randomised to dimethyl fumarate vs**
 483 **usual care**
 484

	Dimethyl fumarate (n=356)	Usual care (n=357)
Age, mean years (SD)	57.5 (16.1)	56.7 (15.3)
≥18 to <70	265 (74%)	271 (76%)
≥70 to <80	61 (17%)	66 (18%)
≥80	30 (8%)	20 (6%)
Sex		
Male	235 (66%)	246 (69%)
Female*	121 (34%)	111 (31%)
Ethnicity		
White	279 (78%)	282 (79%)
BAME	56 (16%)	52 (15%)
Unknown	21 (6%)	23 (6%)
Number of days since symptom onset	9 (7-12)	9 (7-11)
Number of days since hospitalisation	2 (1-3)	1 (1-3)
Oxygen saturation, %	94.0 (92.0-95.0)	94.0 (92.0-96.0)
S/F94	3.2 (1.2)	3.1 (1.1)
Ordinal scale		
2: Not requiring oxygen or medical care	0 (0%)	0 (0%)
3: Requiring medical care but not oxygen	27 (8%)	13 (4%)
4: Requiring oxygen without NIV	257 (72%)	278 (78%)
5: Requiring oxygen with NIV	69 (19%)	66 (18%)
6: Requiring IMV	3 (1%)	0 (0%)
Previous diseases		
Diabetes	92 (26%)	89 (25%)
Heart disease	65 (18%)	49 (14%)
Chronic lung disease	89 (25%)	71 (20%)
Tuberculosis	0 (0%)	0 (0%)
HIV	3 (1%)	1 (<0.5%)
Severe liver disease†	3 (1%)	3 (1%)
Severe kidney impairment‡	8 (2%)	8 (2%)
Any of the above	178 (50%)	161 (45%)
SARS-Cov-2 PCR test result		
Positive	334 (94%)	341 (96%)
Negative	4 (1%)	2 (1%)
Test result not yet known	18 (5%)	14 (4%)
Use of steroids		
Yes	329 (92%)	345 (97%)
No	27 (8%)	12 (3%)

Mean (SD), median (IQR) or n (%) shown.

*No pregnant woman included. †Defined as requiring ongoing specialist care.

‡Defined as estimated glomerular filtration rate <30 mL/min/1.73m²

485
486

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Dimethyl fumarate for COVID-19

487 **Table 2: Effect of allocation to dimethyl fumarate on key study outcomes**

488

	Dimethyl fumarate (n=356)	Usual care (n=357)	Treatment effect (95% CI)	p value
Primary outcome				
Ordinal scale at day 5*				
7 vs 1-6	13 (3.7%)	10 (2.8%)		
6-7 vs 1-5	23 (6.5%)	22 (6.2%)		
5-7 vs 1-4	76 (21.4%)	73 (20.5%)		
4-7 vs 1-3	203 (57.2%)	192 (53.9%)		
3-7 vs 1-2	254 (71.5%)	248 (69.7%)		
2-7 vs 1	268 (75.5%)	260 (73.0%)		
Common odds ratio			1.12 (0.85-1.46)	0.42
Secondary clinical outcomes				
Sustained improvement in ordinal category within 10 days†	246 (69.1%)	258 (72.3%)	0.96 (0.80-1.16)	0.70
Improvement in clinical status at day 10§	246 (69%)	259 (73%)	0.95 (0.87-1.05)	0.31
Baseline-adjusted day 5 S/F94‡	3.58 (0.06)	3.64 (0.06)	-0.06 (-0.22 to 0.10)	0.45
Baseline-adjusted day 5 CRP§	14.4 (1.2)	14.0 (1.2)	2% (-18 to 29%)	0.84
Median duration of hospitalization, days	8	8		
Discharged from hospital alive within 28 days†	274 (77.0%)	281 (78.7%)	0.95 (0.80-1.13)	0.59
Subsidiary clinical outcomes				
Use of ventilation§	58/284 (20%)	60/291 (21%)	0.99 (0.72-1.37)	0.95
Non-invasive ventilation	56/284 (20%)	56/291 (19%)	1.02 (0.73-1.43)	0.89
Invasive mechanical ventilation	14/284 (5%)	12/291 (4%)	1.20 (0.56-2.54)	0.64
Successful cessation of invasive mechanical ventilation**	0/3 (0.0%)	0/0	-	-
Renal dialysis or haemofiltration§	7/356 (2%)	6/355 (2%)	1.16 (0.39-3.43)	0.78
Safety outcomes				
Flushing§				
Some	23 (7%)	11 (3%)	2.08 (1.03-4.21)	0.04
Severe	8 (2%)	0 (0%)	-	-
Subtotal: Any flushing	31 (9%)	11 (3%)	2.81 (1.44-5.50)	0.0026
Gastrointestinal symptoms§				
Some	34 (10%)	18 (5%)	1.88 (1.08-3.27)	0.02
Severe	4 (1%)	1 (0%)	3.99 (0.45-35.51)	0.21
Subtotal: Any gastrointestinal symptoms	38 (11%)	19 (5%)	1.99 (1.17-3.39)	0.01
Transaminitis§	57 (19%)	56 (18%)	1.05 (0.75-1.46)	0.78
Acute kidney injury§	9 (3%)	12 (4%)	0.75 (0.32-1.75)	0.51
Non-coronavirus infection				
Pneumonia	18 (5%)	20 (6%)	0.90 (0.49-1.68)	0.75
Urinary tract	1 (0%)	4 (1%)	0.25 (0.03-2.23)	0.21
Biliary	0 (0.00%)	0 (0.00%)	-	-
Other intra-abdominal	1 (0.28%)	1 (0.28%)	-	-
Blood stream	4 (1%)	1 (0%)	4.01 (0.45-35.71)	0.21
Skin	1 (0.28%)	1 (0.28%)	-	-
Other	6 (2%)	6 (2%)	1.00 (0.33-3.08)	1.00
Subtotal: Any non-coronavirus infection	27 (8%)	31 (9%)	0.87 (0.53-1.43)	0.59

*Number of patients with a 'bad' outcome given. Treatment effects are odds ratios for 'bad' vs 'good' outcome. Common odds ratio estimated using a proportional odds model adjusted for ordinal scale at randomisation. For the 20 patients with missing data on ordinal scale at day 5, the median possible category was imputed (rounded up when there are an even number of possibilities).

†Treatment effect is a rate ratio estimated using logrank methods.

‡Treatment effect is difference in mean S/F94 estimated using ANCOVA with adjustment for baseline S/F94. For patients discharged alive by day 5, a value of 4.76 was imputed. All 135 (18.9%) other missing values at day 5 were imputed using multiple imputation.

§Treatment effect is a risk ratio.

§ANCOVA analyses of log transformed CRP with adjustment for randomisation value were conducted. 276 (38.7%) missing values at day 5 imputed using multiple imputation. Geometric means and approximate standard errors are presented and treatment effect is percentage change in CRP.

||Analyses include only those on no ventilation support at randomisation.

**Analyses restricted to those on invasive mechanical ventilation at randomisation.


||Analyses exclude those on haemodialysis or haemofiltration at randomisation.

489

Figure 1: Trial profile

medRxiv preprint doi: <https://doi.org/10.1101/2022.09.23.22280285>; this version posted September 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



ITT=intention to treat. *Number recruited at sites activated for dimethyl fumarate during period that adult participants could be recruited into dimethyl fumarate comparison.

Figure 2: Distribution of clinical ordinal scale at 5 days by randomised allocation




Figure 3: Effects of allocation to dimethyl fumarate on relative odds of a bad outcome on the clinical ordinal scale at day 5, for each alternative definition of bad outcome

